FDA Opens Public Comment Period on Draft Guidance for Flavored E-Cigarette Applications

Apr.09
FDA Opens Public Comment Period on Draft Guidance for Flavored E-Cigarette Applications
The U.S. Food and Drug Administration’s Center for Tobacco Products announced an open public comment period for a draft guidance titled Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk.

Key Takeaways

 

  • FDA issued the draft guidance on March 11, 2026.
  • The draft is titled Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk.
  • The draft says applicants must show through appropriate studies that a flavored e-cigarette provides enough added benefit for adults who smoke, compared with a tobacco-flavored e-cigarette, to be found appropriate for the protection of public health.
  • Topics discussed include youth use and initiation, a graduated risk-proportionate evaluation, evidence of adult switching or significant cigarette reduction, study approaches for youth risk, and novel device access restriction technology.
  • Public comments may be submitted at regulations.gov under docket number FDA-2026-D-1817 until 11:59 p.m. EDT on May 11, 2026.

 

2Firsts, April 8, 2026 

 

According to FDA CTP Newsroom, the U.S. Food and Drug Administration has opened a public comment period on a draft guidance related to flavored e-cigarette application reviews.

 

FDA issued the draft guidance on March 11

 

FDA said it issued the draft guidance on March 11, 2026, setting out the agency’s current thinking on how it assesses the risk to youth and the level of added benefit to adults needed to outweigh that risk when reviewing applications for flavored e-cigarettes.

 

The draft guidance, titled Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk, addresses in general how much added benefit, compared with a tobacco-flavored e-cigarette, an applicant must demonstrate through appropriate studies for a flavored e-cigarette to be found appropriate for the protection of the public health.

 

The draft covers youth risk, adult benefit, and access restriction technology

 

FDA said the draft guidance discusses several areas related to these types of application reviews, including the role of flavored e-cigarettes in youth use and initiation.

 

The draft also discusses a graduated risk-proportionate evaluation, including the evidence needed to demonstrate sufficient benefit of flavored e-cigarettes for adults who smoke in switching behavior or significant reduction in cigarette use, potential study approaches to assessing the level of risk of youth initiation and use of flavored e-cigarettes, and novel device access restriction technology.

 

Public comments are due by May 11

 

FDA said that if finalized, the draft guidance will represent the agency’s current thinking on the topic. The public may submit comments at regulations.gov under docket number FDA-2026-D-1817.

 

The agency said comments should be submitted by 11:59 p.m. EDT on May 11, 2026, to ensure that FDA considers them before it begins work on the final version of the guidance.

 

Image source: FDA CTP Newsroom.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
STG UK refreshes XQS nicotine pouch packaging: new flavour indicators, hitting retail from March
Scandinavian Tobacco Group UK (STG UK) has announced a rebrand across its XQS nicotine pouch range. The updated packaging will be visible at retail from March, with the recommended retail price remaining £5.50. The new packs feature a bolder logo and glossy textures, retain nicotine strength indicators, and add a side flavour profile indicator to show the flavour type.
Feb.28 by 2FIRSTS.ai
American Snuff Expands Manufacturing Hiring as Reynolds American Builds Future-Ready Operations
American Snuff Expands Manufacturing Hiring as Reynolds American Builds Future-Ready Operations
Reynolds American said American Snuff Company will add more than 50 manufacturing roles at its Clarksville, Tennessee facility as part of its wider U.S. manufacturing investment plan. The company said the hiring is one of the latest developments under its plan to invest more than USD 3.2 billion across U.S. operations by 2030.
Mar.27 by 2FIRSTS.ai
Russia May Allow Regions to Introduce Experimental Vape Sales Bans
Russia May Allow Regions to Introduce Experimental Vape Sales Bans
Russia’s government commission on legislative activity has approved second-reading amendments to a bill on licensing trade in tobacco and nicotine-containing products that would allow Russian regions to introduce experimental bans on vape sales.
Mar.31 by 2FIRSTS.ai
UK reminds vaping firms to apply for new excise duty registration from April 2026
UK reminds vaping firms to apply for new excise duty registration from April 2026
HMRC has issued a reminder urging vaping manufacturers, importers and warehouse operators to prepare for registration under the UK’s new Vaping Products Duty, with applications opening in April 2026 and the duty taking effect in October.
Feb.10
Philippine DTI Says Flavored Vape Products With Minor-Appealing Descriptors Are “100 Percent Smuggled”
Philippine DTI Says Flavored Vape Products With Minor-Appealing Descriptors Are “100 Percent Smuggled”
A Philippine Department of Trade and Industry official told a Senate hearing on vaping regulations that flavored vape products marketed with descriptors attractive to minors are “100 percent smuggled” and did not pass the agency’s licensing process.
Mar.16 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24